Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 21,483 matching trials from the live ClinicalTrials.gov search.
Filters: Boston, Massachusetts Clear all
Completed Phase 3 Interventional Results available

B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B

NCT04193189
View directory record Official record
Conditions
HIV Infection, Hepatitis B
Interventions
HEPLISAV-B, ENGERIX-B
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
638 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
28
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Nov 6, 2026, 2:33 PM EST
Active, not recruiting Phase 1 Interventional

U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

NCT03260491
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
HER3-DXd (FL-DP), HER3-DXd (CTM-1 Lyo-DP), HER3-DXd (CTM-3 Lyo-DP)
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
16
States / cities
Duarte, California • La Jolla, California • Long Beach, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 6, 2026, 2:33 PM EST
Completed Phase 3 Interventional

A Study of Three Drugs Plus Zidovudine in the Prevention of Infections in HIV-Infected Patients

NCT00000991
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Pentamidine isethionate, Sulfamethoxazole-Trimethoprim, Dapsone, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
20
States / cities
Los Angeles, California • Oakland, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Nov 6, 2026, 2:33 PM EST
Completed Not applicable Interventional Results available

Vitamin D Supplementation Reduces Renin-Angiotensin System Activity in Obesity

NCT01068418
View directory record Official record
Conditions
Obesity, Vitamin D Deficiency, Hypertension
Interventions
Vitamin D (cholecalciferol)
Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Nov 6, 2026, 2:33 PM EST
Completed Phase 2 Interventional Results available

Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury

NCT00597818
View directory record Official record
Conditions
NSAID-induced Gastroduodenal Injury, Ulcers, Rheumatoid Arthritis, Osteoarthritis
Interventions
Cobiprostone, Placebo, Non-steroidal anti-inflammatory drug
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
40 Years to 70 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Phoenix, Arizona • Chula Vista, California • Loma Linda, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Nov 6, 2026, 2:33 PM EST
Completed No phase listed Observational

Investigating Phenotypic Profiles of Children and Adolescents With ASD

NCT02700113
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
No intervention
Other
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
4 Years to 18 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Nov 6, 2026, 2:33 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy

NCT00879060
View directory record Official record
Conditions
Myocardial Fibrosis, Hypertrophic Cardiomyopathy
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Nov 6, 2026, 2:33 PM EST
Completed Phase 2 Interventional Results available

Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD

NCT01210560
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
Tolvaptan MR, Tolvaptan IR
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Nov 6, 2026, 2:33 PM EST
Active, not recruiting Phase 2 Interventional Results available

Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]

NCT03747120
View directory record Official record
Conditions
HER2-positive Breast Cancer, Breast Cancer
Interventions
Paclitaxel, Trastuzumab, Pertuzumab, Pembrolizumab
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
5
States / cities
Los Angeles, California • Boston, Massachusetts • Albuquerque, New Mexico + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Nov 6, 2026, 2:33 PM EST
Completed Phase 1 Interventional Results available

Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma

NCT00742924
View directory record Official record
Conditions
Sarcoma
Interventions
cisplatin, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, methotrexate, zoledronic acid, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, filgrastim, Mesna
Drug · Procedure · Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 40 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
77
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 70 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2014 · Synced Nov 6, 2026, 2:33 PM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Mechanisms of Hypoglycemia in Patients Without Diabetes

NCT04428723
View directory record Official record
Conditions
Hypoglycemia
Interventions
Entry of demographic and medical history data into a deidentified database, Blood sample for DNA analysis, Stool sample for microbiome analysis, Mixed meal tolerance test, Continuous glucose monitoring, activity monitor
Other · Genetic · Diagnostic Test
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Nov 6, 2026, 2:33 PM EST
Completed Phase 2Phase 3 Interventional

Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass Procedures

NCT00041925
View directory record Official record
Conditions
Peripheral Vascular Diseases, Arterial Occlusive Diseases, Ischemia, Graft Occlusion, Vascular, Hyperplasia
Interventions
CGT003 (E2F Duplex Decoy)
Drug
Lead sponsor
Anesiva, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
116
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2005 · Synced Nov 6, 2026, 2:33 PM EST
Terminated Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

NCT04048876
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease, Liver Cirrhosis
Interventions
CC-90001, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
64
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Nov 6, 2026, 2:33 PM EST
Terminated Not applicable Interventional Results available

Deviating the Esophagus in Atrial Fibrillation Ablation

NCT01546168
View directory record Official record
Conditions
Esophageal Deviation, Atrial Fibrillation, Ablation
Interventions
esophageal deviation with IDE device
Device
Lead sponsor
Vivek Reddy
Other
Eligibility
18 Years to 80 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Orlando, Florida • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Nov 6, 2026, 2:33 PM EST
Active, not recruiting Phase 2 Interventional

BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)

NCT05156710
View directory record Official record
Conditions
Transplant Rejection
Interventions
BIVV020 (SAR445088), Intravenous immunoglobulin (IVIg), Rituximab or biosimilar, Antithymocyte globulin (ATG), Tacrolimus, Mycophenolate, Corticosteroids
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Nov 6, 2026, 2:33 PM EST
Completed Phase 1 Interventional

Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma

NCT00006024
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumor
Interventions
lomustine, temozolomide
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 21 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
206
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Nov 6, 2026, 2:33 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability of Ubiquinone and Ubiquinol in Older Adults

NCT03020680
View directory record Official record
Conditions
Absorption
Interventions
Coenzyme Q10
Dietary Supplement
Lead sponsor
Tufts University
Other
Eligibility
56 Years to 75 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Nov 6, 2026, 2:33 PM EST
Completed Not applicable Interventional

PREPARE - Primary Prevention Parameters Evaluation

NCT00279279
View directory record Official record
Conditions
Tachycardia, Ventricular, Implantable Cardioverter Defibrillator (ICD), Fibrillation, Ventricular, Syncope
Interventions
Implanted Device
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
31
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2006 · Synced Nov 6, 2026, 2:33 PM EST
Completed Phase 2 Interventional Results available

Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator

NCT01802879
View directory record Official record
Conditions
Hematologic Neoplasms
Interventions
Panobinostat
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
4
States / cities
Duarte, California • Augusta, Georgia • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2019 · Synced Nov 6, 2026, 2:33 PM EST
Completed Not applicable Interventional Results available

PARTNER II Trial: S3iCAP

NCT02687035
View directory record Official record
Conditions
Aortic Stenosis
Interventions
SAPIEN S3 valve
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
1,822 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
55
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 46 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Nov 6, 2026, 2:33 PM EST
Completed Phase 3 Interventional Results available

Treatment of Preschool Children With Upper Respiratory Tract Illnesses Using Azythromycin and Lower Respiratory Tract Symptoms Using Oral Corticosteroids.

NCT01272635
View directory record Official record
Conditions
Asthma, Wheezing
Interventions
Azithromycin, Prednisolone, Placebo Azithromycin, Placebo Prednisolone
Drug · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
12 Months to 71 Months
Enrollment
607 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
16
States / cities
Tucson, Arizona • Oakland, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Nov 6, 2026, 2:33 PM EST
Active, not recruiting No phase listed Observational

OCS Heart Perfusion Post-Approval Registry

NCT05047068
View directory record Official record
Conditions
Transplant
Interventions
OCS Heart System
Device
Lead sponsor
TransMedics
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
27
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Nov 6, 2026, 2:33 PM EST
Completed Phase 3 Interventional Results available

Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

NCT04991935
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
CC-93538
Drug
Lead sponsor
Celgene
Industry
Eligibility
12 Years to 75 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
81
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Nov 6, 2026, 2:33 PM EST
Completed Not applicable Interventional Results available

PROTECTED TAVR: Stroke PROTECTion With SEntinel During Transcatheter Aortic Valve Replacement

NCT04149535
View directory record Official record
Conditions
Stroke
Interventions
Sentinel® Cerebral Protection System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
Not listed
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
41
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Nov 6, 2026, 2:33 PM EST